

# Arcadia Biosciences Inc

03:53 24 Sep 2019

## Arcadia Biosciences wins patent for reduced-gluten wheat, plans direct-to-consumer sales

Arcadia Biosciences Inc (NASDAQ:RKDA) has been granted a patent for its reduced-gluten grains by the US Patent and Trademark office.

The patent is the 17th in Arcadia's GoodWheat portfolio of non-GM, nutritionally-enhanced wheat, which also includes high-fiber resistant starch and extended shelf life varieties.

"This patent reaffirms Arcadia's position as a leader in crop innovation, particularly in optimizing crops for higher nutritional value," Vice President of Research and Development Randy Shultz said in a statement on Monday. "We continue to bring valuable and healthy innovation to wheat — one of the most widely consumed crops in the world — through our GoodWheat portfolio."

The reduced-gluten wheat contains 75% less allergenic gluten than traditional wheat, while also providing increased levels of essential amino acids and improved protein quality.

### READ: Arcadia Biosciences closes registered direct offering that raised about \$10 million

Arcadia plans to retail a reduced-gluten flour later this year, its first direct-to-consumer offering. Foods made using the GoodWheat flour don't suffer any dropoff in quality, texture or taste, the company said.

"This is really an exciting time for Arcadia's GoodWheat portfolio," Chief Commercial Officer Sarah Reiter said in a statement. "Our newest offering caters to a growing number of consumers looking to reduce their gluten intake, either as a result of a wheat sensitivity or simply because they feel or perform better when following a diet with lower levels of gluten."

According to research from The Cornell Group, there's a subset of the population looking to do exactly that. They found that 26% of consumers reported that they were seeking to reduce gluten in their diet or cut it altogether.

Another promising sign comes from the Global Gluten Free Products Market Research Report, which estimates that the gluten-free products market will reach \$9.14 billion by 2023.

Arcadia shares rose almost 1% to \$5.35 on Monday.

—Updated to include stock movement—

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 3.07

**Market Cap:** \$32.85 m

### 1 Year Share Price Graph



September 2019 March 2020 September 2020

### Share Information

**Code:** RKDA

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	6.63	2.35

**Sector:** Agribusiness

**Website:** [arcadiabio.com](http://arcadiabio.com)

### Company Synopsis:

*Arcadia Biosciences is a consumer-driven agricultural technology company that develops and commercializes high-value food ingredients, nutritional oils and products that help meet consumer demand for a healthier diet. Our GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace.*

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).